Patient-derived human-in-mouse xenograft models of breast cancer (PDX models) that exhibit spontaneous lung metastases offer a potentially powerful model of cancer metastasis. In this study, we evaluated the malignant character of lung micrometastases that emerge in such models after orthotopic implantation of human breast tumor cells into the mouse mammary fat pad. Interestingly, relative to the parental primary breast tumors, the lung metastasis (met)-derived mammary tumors exhibited a slower growth rate and a reduced metastatic potential with a more differentiated epithelial status. Epigenetic correlates were determined by gene array analyses. Lung met-derived tumors displayed differential expression of negative regulators of cell proliferation and metabolism and positive regulators of mammary epithelial differentiation. Clinically, this signature correlated with breast tumor subtypes. We identified hsa-miR-138 (miR-138) as a novel regulator of invasion and epithelial-mesenchymal transition in breast cancer cells, acting by directly targeting the polycomb epigenetic regulator EZH2. Mechanistic investigations showed that GATA3 transcriptionally controlled miR-138 levels in lung metastases. Notably, the miR-138 activity signature served as a novel independent prognostic marker for patient survival beyond traditional pathologic variables, intrinsic subtypes, or a proliferation gene signature. Our results highlight the loss of malignant character in some lung micrometastatic lesions and the epigenetic regulation of this phenotype. Cancer Res; 74(24); 7406-17. Ó2014 AACR.
Introduction
Metastasis can occur at the very early stages of cancer disease, especially in the form of micrometastatic lesions (1, 2) . The multistep process of metastasis comprises tumor cell invasion to surrounding tissue, intravasation to vascular or lymphatic structures, survival in circulation, homing and extravasation to distant organs, and colonization with distant tumor growth (3) . An open debate in cancer research focuses on whether the metastatic tumor cells in distant organs, such as the lungs, possess a more metastatic potential than the primary tumor cells. Another important related question is what morphologic and epigenetic features may be dynamically acquired or selected within spontaneous metastases.
By tail vein injection and in vivo selection of MDA-MB-231 breast cancer cells in the lungs, Minn and colleagues isolated lung-tropic LM1 and LM2 cells with increased lung metastatic capacity upon tail vein injection (4) . However, this blood stream inoculation approach bypasses the first two steps of metastasis: invasion and intravasation. In contrast, we wanted to determine whether the lung metastases spontaneously developed from breast tumors carry more malignant features compared with the parent tumor cells.
To generate spontaneous metastasis models representing human disease, we have previously employed an orthotopic implantation approach to xenograft human breast tumor specimens into NOD/SCID or NSG mouse mammary fat pads, called patient-derived human-in-mouse breast tumor xenograft (PDX) models (5) . Most of our established metastatic PDX models with spontaneous pulmonary micrometastases are triple negative for estrogen receptor (ER), progesterone receptor (PR), and HER 2 expression (ER À PR À HER2 À ; ref. 5 ). On the basis of gene expression profiles, breast tumors are also divided into six intrinsic molecular subtypes: normal-like, luminal A, luminal B, claudin-low, basal-like, and HER2-enriched (6, 7) . The advantages of classifying six molecular subtypes include distinct clinical implications and prognosis correlations. Basallike tumors are one of the most aggressive subtypes with the worst patient prognosis (6, 7) . A majority, but not all, of the triple-negative breast tumors belong to the basal-like subtype (8) , which can be determined by prediction analysis of microarray 50 (PAM50; ref. 9) .
We focused on a few triple-negative, metastatic breast tumor models ("parental" primary tumors) with basal-like characteristics and set out to determine whether their spontaneous lung metastases remain malignant after being reimplanted back into mouse mammary fat pads to form "metderived" mammary tumors. We originally expected that the met-derived mammary tumor models upon orthotopic reimplantation would be more aggressive and metastatic than the parental primary tumors. Surprisingly, we found that certain lung met-derived mammary tumors were less metastatic than routinely passaged parental tumors in NOD/SCID mice. Because these two models originated from the same patient with minimal, if any, genetic alterations, we hypothesized that epigenetic regulations contributed significantly to the differential metastatic capacity of these models.
MicroRNAs (miRNA, miR) have emerged as critical epigenetic regulators of stem cell functions, epithelial-mesenchymal transition (EMT), and metastasis (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . With the combined approaches of gene expression arrays and global miRNA analyses, we identified genes, miRNAs, and their pathways that had altered expression levels in the lung met-derived tumor model and also regulated the growth and invasion of breast cancer cells. Further clinical data analyses based on multiple independent datasets confirmed the clinical relevance of our discoveries and the prognostic value of the candidate miR-138 activity signature.
Materials and Methods

Animal studies
Human-in-mouse breast tumor models with spontaneous metastases were generated using patient tumors (5) . Experiments were performed under the approval of the Institutional Biosafety Committee, Institutional Review Board, and the Administrative Panel on Laboratory Animal Care of Case Western Reserve University and the University of Chicago.
Tumor dissociation and transplantation in mice
As previously described, tumors were dissociated with collagenase III (Worthington) and DNase I (Sigma; ref. 5). Red blood cells were lysed with ACK lysis buffer (Invitrogen). Dissociated tumor cells were stained with CD44-APC, H2Kdbiotin and strepavidin-PE-cy7 (BD), and DAPI in HBSS/2% FBS for further flow analysis or sorting on FacsAriaII (BD). Tumor cells were mixed 1:1 with Matrigel (BD) and transplanted into NOD/SCID mouse mammary fad pads.
Bioluminescence imaging
Mice were injected i.p. with D-luciferin (30 mg/mL, Biosynth AG) and anesthetized with isoflurane (2% in 1 L/min oxygen; ref. 5) . Bioluminescence images (0.1 seconds to 5 minutes) were acquired 10 to 15 minutes after D-luciferin injection using the IVIS Spectrum system (Caliper). For ex vivo bioluminescence imaging (BLI) of dissected lungs and tumors, D-luciferin (300 mg/mL in PBS) was used to soak freshly isolated lungs or tumors for 2 to 3 minutes before imaging. Data were analyzed using LivingImage 2.5 Software (Caliper) and expressed as total flux (photons/second).
Gene expression microarray analyses
Samples were profiled as described previously using oligo microarrays (Agilent Technologies; ref. 22) . All microarray data are available in the University of North Carolina (UNC) Microarray Database and have been deposited in the Gene Expression Omnibus (GEO) under the accession number GEO-GSE 59750. Each gene signature (i.e., met-derived and miR-138) was derived by comparing two groups using an unpaired two-class significance analysis of microarrays (SAM). The miR-138 signature of up-and downregulated genes was then summarized as a single "activity score" by multiplying the SAM score of each gene by its expression value in the tested sample and then summing all of the values of each sample.
Cell lines and transfections
MDA-MB-231, BT-20, and Hek293Ts were obtained from the ATCC and cultured for less than 6 months. ATCC verified the cell lines using short tandem repeat profiling. Cells were maintained at 10% FBS þ 1% penicillin-streptomycin in DMEM (MDA-MB-231, Hek293T, with G418) and EMEM (BT-20). MiRNAs (Dharmacon, negative control #4) were transfected at 100 nmol/L (MDA-MB-231) or 50 nmol/L (BT-20, Hek293T) and repeated on subsequent days. 3 0 Untranslated region (3 0 UTR) luciferase vectors and cDNA vectors were transfected using Fugene (Roche-Promega). For target gene rescue experiments, cells were transfected twice with cDNA vectors after two miRNA transfections.
Quantitative invasion assays in vitro
MDA-MB-231 cells were plated in serum-free DMEM to the top of 8-mm Transwell inserts (BD) precoated 1:100 with growth factor-reduced Matrigel (BD) in 24-well companion plates (BD) containing DMEM þ 10% FBS (no gradient for controls). After 24 hours, cells were stained for one hour at 37 C in HBSS þ 4 mg/mL calcein AM (BD). Cells on the top of inserts were removed using cotton swabs, and invaded cells were dissociated using dissociation buffer (Trevigen; shaken for an hour at 37 C), and read at 485/535 nm.
Cell growth assays
MDA-MB-231 cells were plated in 24-well plates in DMEM þ 10% FBS þ1% penicillin-streptomycin one day before starting analysis. Cells were trypsinized and counted using tryphan blue and hemacytometer every day for four days. Each time point was an average of three wells.
Western blot
MDA-MB-231 cells were plated in 10 cm dishes and harvested 48 hours after transfections. Cells were lysed and sonicated in RIPA buffer, and 100 mg of total protein was loaded onto 4% to 20% gradient gels for immunoblots with antibodies to EZH2 (BD biosciences) and b-actin (Sigma-Aldrich; AC-15). Fluorescence-conjugated secondary antibody (red for b-actin and green for others) was used, and blots were read using Odyssey (Li-Cor).
RNA extraction and miRNA real-time PCR
Total RNAs for array analysis were extracted from culture cells or frozen tumor samples using TRIzol (Invitrogen) and cleaned using the RNeasy Mini Kit (Qiagen). RNAs from sorted cell populations were precipitated with isopropanol and glycogen (Invitrogen). Reverse transcription reactions and realtime PCR for miRNAs were performed using the Taqman microRNA reverse transcription Kit and individual miRNA primers (Applied Biosystems). Real-time PCR was performed in the Onestep Real-Time PCR System (Applied Biosystems).
Apoptosis and sub-G 1 population
MDA-MB-231 cells were plated in 12-well plates and transfected as above. Both adherent and floated cells were collected at 24 or 72 hours and fixed in 70% ethanol and then stained with propidium iodide (Sigma). DNA content was analyzed using BD LSRII flow cytometer.
Immunofluorescence, immunohistochemistry, and phase contrast imaging
MDA-MB-231 cells were plated on microscope slide wells (Millipore) and transfected. For F-actin staining, cells were fixed in 4% paraformaldehyde/PBS and stained with fluorescent phalloidin (Invitrogen F432) and SlowFade Gold antifade reagent with DAPI (Invitrogen). Cell images were taken under Axiovert 100tv (fluorescent; Zeiss). Tumor and lung samples were fixed in 10% neutral buffered formalin, embedded, and sectioned into 5-mm thin tissue sections. IHC staining was performed using antibodies to hEZH2 (BD Biosciences) at Histology Core Facility. Images were taken by Pannoramic Scan Whole Slide Scanner (CRi, Cambrige Research and Instrumentation).
Statistical analysis
For all assays and analyses in vitro, a Student t test was used to evaluate the significance. For animal studies, tumor growth curves and lung metastases were analyzed using a linear mixed model or Wilcoxon rank-sum test in R software.
Additional method information including detailed statistical analysis methods can be found in Supplementary Data.
Results
Generation of a lung met-derived breast tumor model
On the basis of the previously developed human-in-mouse triple-negative breast tumor models that exhibited spontaneous pulmonary micrometastases (5), we term these primary tumor models as "parental" models, such as metastatic-1 (M1parental), which belongs to the basal-like subtype. To further examine the metastatic potential of lung metastases (mets), we dissociated tumor cells from M1 lung mets and then engrafted the cells back into the mammary fat pads of new recipient mice. Consequently, a second breast tumor xenograft model was established as M1 lung metastasis-derived mammary tumor model, termed as "M1-met-derived", in contrast to the normally passaged M1-parental breast tumor model ( Fig. 1A) , both grown in the mouse mammary fat pads to exclude the effects of different microenvironments between the primary and distant sites.
The tumor cells from both the parental tumor model and the met-derived model were labeled with a luciferase 2-tdTomato fusion vector pFU-L2T (5) to allow for the monitoring of growth and metastasis using BLI ( Fig. 1A) . Measured by a caliper as well as BLI, the mammary tumors of the met-derived model had a slower growth rate compared with that of the parental tumors, replicated with multiple lung metastases isolated from seven different mice of the M1 parental model ( Fig. 1B and C). Specifically, it took met-derived mammary tumors 90 days on average to form palpable tumors that were comparable in size with the parental tumors formed on average in 60 days ( Fig. 1D ). In addition to tumor growth, BLI of the dissected lungs from breast tumor-bearing mice showed that the met-derived tumors exhibited reduced lung micrometastases than the parental tumors ( Fig. 1D ). These data suggest that the lung met-derived tumor models do not necessarily remain aggressive but instead become less malignant compared with the parental breast tumor models.
To further understand what could be responsible for the altered tumor growth and lung metastasis in the met-derived model, we performed both mRNA microarrays and global miRNA real-time PCR analyses.
Global gene expression alterations in the met-derived breast tumors
By gene expression microarray analyses, the met-derived tumors showed 934 upregulated probes (corresponding to 686 genes) and 297 downregulated probes (corresponding to 229 genes), compared with the basal-like parental tumors [false discovery rate (FDR) < 5%; Fig. 2A and Supplementary Table  S1 ]. Many of the upregulated genes in the met-derived tumors were related to cell adhesion and differentiation as well as tumor suppressors and cell cycle inhibitors, such as KRT19 (CK19), CEACAM1 (CD66a), and CDKN1A ( Fig. 2A and Supplementary Table S1 ). Many of the downregulated genes were promoters of self-renewal, cell motility, and cell cycle, such as EZH2, SMAD2, and CCNB1 ( Fig. 2A and Supplementary Table  S1 ). We then used a differentiation predictor that measures each sample's position along a normal mammary developmental axis from mammary stem cell, luminal progenitor, and mature luminal cell states (23) . Consistently, the differentiation scores of the lung met-derived tumors were significantly higher than those of the primary tumors (P ¼ 0.007; Supplementary Fig. S1 ).
To further link the met-derived gene signatures to breast cancer intrinsic subtypes, we examined the mean expression pattern of the upregulated and downregulated genes across the UNC337 database (23) . The up-and downregulated genes in the met-derived model were found highly expressed in the subset of normal-like, luminal A, and claudin-low subtypes and relatively lowly expressed in the other subset of three subtypes: luminal B, HER2-enriched, and basal-like (P < 0.0001, Student t test; Fig. 2B ). Thus, the met-derived signature was found more enriched in luminal A and normal-like with good outcomes than in poor outcome and undifferentiated tumor subtypes (i.e., luminal B, HER2-enriched, and basal-like; Fig. 2B ). However, it is surprising that the met-derived signature with a list of cell adhesion and differentiation genes is highly expressed in claudin-low, which shows low expression of claudins 3, 4, 7 and not necessarily good outcomes (23) .
By IHC staining and flow cytometry analyses, we further validated the differential expression of representative genes at the protein level. CK19 is a luminal epithelial cell marker with a favorable prognosis in patients with breast cancer (24) . EZH2 regulates self-renewal and it promotes tumor growth and metastasis (25) (26) (27) . CK19 was upregulated and EZH2 was downregulated in met-derived tumor sections ( Fig. 2C ). CD66a is a mammary epithelial cell differentiation marker (28) and a suppressor of cell proliferation and tumorigenesis (29, 30) . By flow analyses, we observed a 27.2% increase of CD66a-positive cells in the met-derived model compared with that of the parental tumor ( Fig. 2D ). All these markers confirmed a more differentiated status of met-derived breast tumors versus parental breast tumors.
To validate that the altered gene expression accumulated in the pulmonary metastases, we sorted tumor cells directly from the lung metastases of the parental models M1 and another independent model, Metastatic-2 (M2), which is derived from a second triple-negative patient tumor (5) . Measured by realtime PCR, EZH2 expression decreased in the pulmonary metastatic cells compared with the paired primary tumor cells in both M1 and M2 models ( Fig. 2E ). These data suggest that the altered gene expression in the met-derived model occurs in the pulmonary metastatic site before re-engraftment.
Importing the 492 genes into DAVID (The Database for Annotation, Visualization and Integrated Discovery, http:// david.abcc.ncifcrf.gov/) revealed they were enriched in pathways related to cell proliferation, cytoskeleton, and cell-cycle processes ( Supplementary Table S2 ). 
Differentially expressed miRNAs in the met-derived breast tumors
To identify candidate miRNAs that may regulate cell cycle, apoptosis, and metastasis (10-21), we performed real-time PCR analyses for 384 miRNAs in both parental and metderived tumors. Thirty-two miRNAs were differentially expressed with 27 miRNAs being upregulated in the metderived tumors, including miR-200 family members, miR-138, and others ( Supplementary Table S3 ). The global upregulation of miRNA expression might suggest a relatively benign status for the met-derived breast tumors, as aggressive tumors have a greater majority of downregulated miRNAs in their expression profiles (31) .
The upregulated miRNAs contained a few luminal subtype miRNAs, such as known miR-200, miR-29, and miR-30 family members (22, 32, 33) . On the basis of the miRNA expression profiles of the human breast tumors we collected at the University of Chicago (GSE39543; ref. 22 ), a few miRNAs displayed differential expression profiles across the subtypes of clinical breast tumors, including miR-138-1 Ã , miR-143, miR-26b, and miR-331-3p with downregulated levels in triple-negative tumors versus non-triple-negative tumors, and miR-576-3p upregulated in tumors versus normal breast tissue adjacent to tumors ( Supplementary Fig. S2 ). However, miR-138-1 Ã is not the candidate miR-138 but the 3 0 passenger strand produced from the miR-138-1 precursor during miRNA maturation. From the analyses of GSE37407 (34) with paired primary tumors with metastatic tumors (both lymph nodes and distant organs) from 14 patients with breast tumor, we found that miR-138, along with miR-138-1 Ã and miR-138-2 Ã , was upregulated in the metastases compared with the paired primary tumors (n ¼ 23, P < 0.05 or <0.01; Supplementary Fig. S3A and S3B) .
We subsequently characterized the functions as well as regulation of candidate miRNAs, and then identified their direct target genes in regulating breast cancer phenotypes.
MiR-138 regulates breast cancer cell invasion, growth, and EMT
From the selected miRNA candidates with potential clinical relevance ( Supplementary Figs. S2 and S3 ), we further characterized their role in regulating breast cancer cell invasion and proliferation. Although most of the chosen miRNAs, such as miR-143, miR-26b, and miR-331-5p, did not show effects on invasion in the screening assays, enforced expression of miR-138 suppressed invasion in both MDA-MB-231 and BT-20 cells (Fig. 3A) . The level of miR-138 was vastly upregulated in the met-derived model versus parental tumor model ( Fig. 3A and Supplementary Table S3 ).
Furthermore, we examined whether upregulated miR-138 contributed to the slower growth rate of the met-derived tumor model. In the cell counting assay, enforced expression of miR-138 inhibited the proliferation of breast tumor cells ( Fig.  3C ). Cell-cycle and apoptosis analyses using propidium iodide staining showed that miR-138 slightly increased the percentage of sub-G 1 apoptotic cells at the early (24 hours) and late (72 hours) time points and induced G 1 arrest at 72 hours after transfection (Fig. 3D ). Phalloidin staining revealed that increased levels of miR-138 reduced F-actin-associated stress fibers (22, 33) and promoted a rounder and more epithelial-like cell phenotype in MDA-MB-231 cells ( Fig. 3E and F ), suggesting that miR-138 inhibits EMT, which is important for invasion at the early stage of metastasis.
GATA3 regulates miR-138 in breast cancer metastasis
To examine what mechanisms caused the increased level of miR-138 in the lung-derived model, we performed FISH staining to detect the copy number of the miR-138 gene in both tumor models. There were equal numbers (three per cell on average) of the miR-138 gene present in both parental and met-derived tumor models ( Supplementary Fig. S4 ), indicating that copy number change was not a factor involved in the increased level in the lung-derived model.
We then hypothesized that miR-138 might be transcriptionally regulated in the lung metastases. Within the putative promoter regions (À3kb) of mir-138-1 and mir-138-2 genes, JASPAR online analyses (35) revealed multiple GATA3 binding sites located upstream of both genes ( Supplementary Table  S4 ). We then analyzed the expression of miR-138 and GATA3 by real-time PCR in paired lung metastases and primary tumor cells sorted from M1 and M2 models. Both miR-138 and GATA3 were upregulated in the lung metastases compared with paired primary tumor cells ( Fig. 4A and B ). In addition, forced expression of wild-type GATA3 induced a significant increase (8-to 10-fold) of miR-138 levels in MDA-MB-231 cells (Fig. 4C) .
To further determine whether GATA3 functionally interacts with the mir-138 promoters (138-1 and 138-2), we cloned the putative promoter regions (À3kb) into the luciferase reporter vector pGL4. We detected a positive transcriptional regulation of the luciferase reporter gene by GATA3 through inserted promoter regions of mir-138-1 or mir-138-2 genes (Fig. 4D ), which harbor two or three putative GATA3 binding sites, respectively ( Supplementary Table S4 ). These data indicate that GATA3 transcriptionally promotes miR-138 expression in the lung metastases.
Identification of miR-138 activity gene signature
Individual miRNAs regulate mRNAs of up to hundreds of genes, which renders miRNAs as powerful regulators (36) . To test the hypothesis that miRNAs contribute to the altered gene expression profile of the met-derived tumor models, we examined the effects of miR-138 on global gene expression. The microarray analysis of MDA-MB-231 cells upon miR-138 transfection revealed a miR-138 gene signature (FDR < 8.5%), with 121 downregulated probes (corresponding to 96 genes) and 3 upregulated probes (corresponding to three genes; Fig. 5A and Supplementary Table S5 ).
We compared the genes downregulated by miR-138 with the ones downregulated in met-derived models and found two common genes, EZH2 and TYMS ( Figs. 2A and 5A , Supplementary Tables S1 and S5 ). However, GO analyses of the downregulated genes suggested a total of 32 common biologic processes altered in both miR-138-expressing cells and in the met-derived models ( Fig. 5A; Supplementary Tables S1 and S5 ). The pathways regulated by miR-138 included metabolic processes (EZH2, IL11, etc.), DNA metabolic processes (CCND3, CCNE2, MCM3, PCNA, RRM2, H2AFX, etc.), cellular response to stress (TYMS), and EMT (VIM; Fig. 5A and Supplementary  Table S5 ). We identified the similar expression pattern of miR-138 downregulated genes (Fig. 5B) , as that of downregulated genes in the met-derived gene signature across breast tumor subtypes in UNC337 (Fig. 2B ), suggesting that miR-138 may contribute to the altered gene expression in the metderived model.
To complement the limited sample size of patient tumors with both miRNA and clinical-pathologic analyses, we employed a global gene signature regulated by miR-138 to mirror the expression and activity status of miR-138 in tumor samples, termed as "miR-138 activity gene signature," which is distinct and opposite to miR-138 downregulated genes. We evaluated the activity of the miR-138 gene signature across the intrinsic subtypes in UNC337. Mirroring the pattern of upregulated genes in the met-derived gene signature (Fig. 2B) , a high activity of miR-138 was found in normal-like, luminal A, and claudin-low subtypes, and miR-138 activity was downregulated in poor outcome and undifferentiated tumor subtypes (i.e., basal-like, HER2 enriched, and luminal B; Fig. 5C,  left) .
Furthermore, we determined the prognostic value of the miR-138 activity signature using two independent breast tumor datasets, METABRIC (n ¼ 1848; ref. 37) and MDACC588 (n ¼ 588; ref. 38) . Kaplan-Meier (KM) plots showed that patient tumors with high miR-138 activity gene expression correlated with an increased probability of breast cancer-specific survival or distant relapse-free survival (Fig.  5C, right; Supplementary Fig. S5 signature (39, 40) in the METABRIC dataset (n ¼ 1848, adjusted P < 0.05; Supplementary Table S6 ).
EZH2 is an essential direct target of miR-138 MiRNAs regulate gene expression by targeting the 3 0 UTR of the relevant mRNAs. To strategically identify the important direct targets of miR-138, we performed the GeneSet2miR prediction (41) with the list of downregulated genes (Supplementary Table S5 ) and validated the genes using experimental analyses, such as real-time PCR, immunoblots, luciferase assays, and functional rescue studies.
Four of 13 algorithms of the GeneSet2miR analyses (41) predicted 9 of the 121 downregulated genes as direct target genes of miR-138, including EZH2 and PPIP5K1 (Supplementary Fig. S6A ). We also found the EMT marker VIM predicted as a miR-138 target by one algorithm. Real-time PCR analyses of four chosen genes validated microarray data in which miR-138 inhibited mRNA expression levels of EZH2, PPIP5K1, VIM, and IL11 in MDA-MB-231 cells ( Supplementary Fig. S6B and S6C ). Immunoblotting and ELISA analyses also confirmed miR-138-mediated inhibition of target genes EZH2 and IL11 at protein levels, respectively ( Fig. 6A and Supplementary Fig. S6D ). Luciferase assays with the 3 0 UTR of the candidate genes cloned upstream of the luciferase gene demonstrated that miR-138 interacts with the 3 0 UTR of EZH2, PPIP5K1, and VIM and induces an inhibitory effect on the expression of these target genes ( Supplementary Fig. S6E and S6F) .
To determine the importance of the target genes, we performed rescue experiments in which candidate cDNA was overexpressed in MDA-MB-231 cells to compensate for the increased levels of miR-138. EZH2 was able to restore the invasiveness of breast tumor cells back to the control levels in the presence of transfected miR-138 ( Fig. 6B ). Knockdown of EZH2 by siRNAs mimicked the inhibitory effect of miR-138 on two cytoskeleton markers of EMT (22, 33) , F-actin, and focal adhesion (vinculin; Fig. 6C ). These data demonstrate that EZH2 is an essential target of miR-138 in regulating both breast tumor invasion and EMT.
We further compared the expression pattern of EZH2 across the intrinsic breast cancer subtypes. EZH2 showed similar 8.19eÀ40 ). C, left, miR-138 activity signature across the intrinsic subtypes of breast cancer based on the UNC337 dataset (n ¼ 320; P ¼ 2.09eÀ37). Right, Kaplan-Meier curves of survival outcomes based on miR-138 activity score signature to predict breast cancer-specific survival in the METABRIC dataset (n ¼ 1,848; P < 0.0001). Samples were rank ordered based on their scores and grouped based on quartiles. MVAs show adjusted P value <0.05 based on the classical pathologic variables, intrinsic subtypes, and proliferation signature ( Supplementary Table S6 ).
expression patterns across subtypes as those genes downregulated in met-derived tumors and those targeted by miR-138, namely higher expression in poor prognostic and undifferentiated subtypes such as basal-like, HER2-enriched, and luminal B (Figs. 2B, 5B , and 6D). Concordant with these findings, higher EZH2 expression was associated with ERnegative status by IHC in 50 tumor samples from the University of Chicago tumor dataset ( Supplementary Fig. S6G ). These data suggest that EZH2 is a relevant regulator of breast cancer.
Discussion
In this study, we report that in contrast to the malignant primary tumors, the spontaneous pulmonary metastases developed in PDX models can lose their metastatic potential and mesenchymal status and gain a more epithelial and differentiated status. This feature might be generalized to a group of patients with breast cancer with tumor metastases in the brain, liver, and lymph nodes (34) . This phenomenon had initially been unexpected and was against the EMT dogma proposed in metastasis (42) . However, more and more studies support that MET along with an epithelial state is required for colonization at the late stage of metastasis (43) (44) (45) . Although there is still debate in the field, our studies indicate that metastasis is a complex procedure and the tumor cells that make it to the last step of colonization may not necessarily be very proliferative and mobile again. Similarly, an acquired luminal and nonmetastatic feature had been previously observed in certain breast cancer cell lines derived from the metastatic sites of breast tumors, such as MCF-7 (46) which is derived from pulmonary metastases (pleural effusions) of a patient with invasive breast cancer, but has lost the invasive and mesenchymal features of primary tumors and gained an epithelial phenotype with CK19 and ER expression (47) . The open question is whether selection or adaptation plays a more important role in this phenomenon. Consistent with our findings of an altered expression of the miR200 family members in the epithelial lung met-derived models, the recent study on paired metastases and primary tumors of patients with breast cancer also demonstrates an increased epithelial feature (E-cadherin expression) along with elevated expression of miR-200 family members in almost all of the distant metastasis and lymph nodes compared with corresponding primary tumors (34) . Furthermore, certain ER À primary tumors might gain ER expression in their brain metastases, although other ER þ primary tumors might still maintain or lose ER expression in distant metastases and lymph nodes (34) . A future comprehensive analysis will be necessary to examine the global gene expression of paired metastases and primary tumors of breast cancer.
Nevertheless, the distinct properties of the met-derived breast tumor models versus parental tumors have served as a great model system for us to examine the epigenetic regulation (and possibly genetic selection) process of tumor cells during metastasis. Gene and miRNA expression profile comparisons have led us to identify new pairs of miRNA/gene regulators, such as miR-138 and EZH2. Interestingly, EZH2 is not only a representative gene downregulated in the metderived model, but also a direct and important target of miR-138, which is oppositely upregulated in that model and regulates EMT. EZH2 is a chromatin-bound component of PRC complex II and plays a critical and powerful role in self-renewal and tumor progression in lymphoma, breast cancer, and prostate cancer (48) (49) (50) (51) . Previous data have reported that EZH2 directly binds to the promoter of vinculin, a marker of focal adhesion and EMT (24) . The clinical relevance of both EZH2 and miR-138 activity gene signature implies innovative biomarkers and targets in human breast cancer development and progression.
Although our previous data suggest that IL11 plays a role in breast tumor invasion and EMT (22, 33) , IL11 is not on the list of direct targets and is likely an indirect target of miR-138. Because IL11 is a target of NF-kB (52), there is a possible regulation of IL11 by EZH2. Although EZH2 binds to RelA/RelB directly in basal-like breast cancer cells to promote expression of NF-kB targets (53) , EZH2 may also positively regulate IL11 in the basal-like breast tumors.
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